IceCure Medical Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.3M
- Price
- $1.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.45%
- Volume
- 355.4K
About
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
Quick stats
Shares outstanding4.6M
Computed float3.5M
Float / shares76.2%
Cash runway (months)5.6
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001584371
AI Summary
AI-generated1/31
minorbullishclinical trial
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical added Legacy Health's Good Samaritan Medical Center in Portland, Oregon as a new U.S. clinical site for its FDA-approved post-market ChoICE Study of ProSense® cryoablation in low-risk breast cancer.
Dr. Nathalie Johnson, Senior Medical Director of the Legacy Cancer Institute, joins as a co-primary investigator, with Marco Aru and Jennifer Garreau serving as site co-investigators.
The ChoICE Study is expected to enroll approximately 400 patients across up to 30 U.S. sites, generating real-world evidence supporting cryoablation as a minimally invasive alternative to surgery.